YTHDC1 and acute myeloid leukemia: Differently, MLOs driven by m6A modifications, such as nuclear YTHDC1-m6A condensates (nYACs), protect oncogenic mRNAs from degradation by polyA tail exosome targeting complex (PAXT), which contributes to the survival of cancer cells in acute myeloid leukemia 26.